You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

squamous cell carcinoma of the esophagus

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Esophagus Squamous Cell Carcinoma Trial in Beijing (Palbociclib, Afatinib)

Recruiting
  • Esophagus Squamous Cell Carcinoma
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
May 17, 2023

ctDNA-MRD in Predicting Efficacy of Esophageal Squamous Cell

Not yet recruiting
  • Squamous Cell Carcinoma of Esophagus
    • (no location specified)
    Feb 25, 2023

    Esophagus Cancer Trial in Tianjin (Camrelizumab, Paclitaxel, Cisplatin)

    Recruiting
    • Esophagus Cancer
    • Tianjin, Tianjin, China
      Affiliated Cancer Hospital of Tianjin Medical University
    Nov 24, 2022

    Locally Advanced Esophageal Carcinoma Trial in Nanjing (Neoadjuvant Chemotherapy, Neoadjuvant Toripalimab, Short Course

    Recruiting
    • Locally Advanced Esophageal Carcinoma
    • Neoadjuvant Chemotherapy
    • +2 more
    • Nanjing, Jiangsu, China
      Jiangsu Cancer Hospital /Jiangsu Institute of Cancer Research
    Jun 21, 2022

    Immunotherapy Esophagus Cancer Trial (Tislelizumab, Albumin paclitaxel, Nedaplatin)

    Not yet recruiting
    • Immunotherapy Esophagus Cancer
    • (no location specified)
    Aug 24, 2022

    Esophagus Cancer Trial in Guangzhou (Cadonilimab, Paclitaxel and cisplatin, intensity-modulated radiotherapy)

    Not yet recruiting
    • Esophagus Cancer
    • Guangzhou, Guangdong, China
      Sun Yat-sen University
    Nov 20, 2023

    Esophageal Carcinoma, Esophagogastric Junction Carcinoma Trial (pembrolizumab)

    Completed
    Has Results
    • Esophageal Carcinoma
    • Esophagogastric Junction Carcinoma
    • pembrolizumab
    • (no location specified)
    Aug 18, 2022

    Primary Tumor Burden Score:A Novel Staging Parameter for ESCC

    Completed
    • Neoplasm, Esophagus
    • Neoplasm, Squamous Cell
    • nCRT
    • (no location specified)
    Apr 20, 2023

    Esophagus Cancer Trial in Xiamen (Tislelizumab, Paclitaxel-albumin, Carboplatin)

    Recruiting
    • Esophagus Cancer
    • Xiamen, Fujian, China
      ShanghaiZhongshan
    Apr 8, 2023

    Esophagus Cancer, Esophageal Cancer, Esophageal Tumors Trial in Pittsburgh (ActivSight)

    Not yet recruiting
    • Esophagus Cancer
    • +9 more
    • ActivSight
    • Pittsburgh, Pennsylvania
      University of Pittsburgh Medical Center - Dept of Cardiothoracic
    Jan 31, 2023

    Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma Trial in Guangzhou

    Recruiting
    • Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma
    • Tucidinostat (chidamide) and PD-1 inhibitor （Toripalimab）
    • Guangzhou, Guangdong, China
      Cancer center of Sun Yat-sen University
    Jul 20, 2022

    Stage IV Esophagus Squamous Cell Carcinoma Trial in Hangzhou (Camrelizumab, Irinotecan, Paclitaxel)

    Not yet recruiting
    • Stage IV Esophagus Squamous Cell Carcinoma
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    Apr 2, 2022

    Esophageal Carcinoma, Esophagogastric Junction Carcinoma Trial (pembrolizumab, paclitaxel, docetaxel)

    Completed
    Has Results
    • Esophageal Carcinoma
    • Esophagogastric Junction Carcinoma
    • pembrolizumab
    • +3 more
    • (no location specified)
    May 5, 2022

    Esophageal Cancer, Squamous Cell Esophagus Cancer, Adenocarcinoma Esophagus Trial in Boston (Pembrolizumab)

    Active, not recruiting
    Has Results
    • Esophageal Cancer
    • +2 more
    • Boston, Massachusetts
    • +2 more
    Apr 7, 2022

    Esophagus SCC Trial in Jinan (Sintilimab Injection plus Paclitaxel and Cisplatin, Paclitaxel and Cisplatin)

    Withdrawn
    • Esophagus SCC
    • Sintilimab Injection plus Paclitaxel and Cisplatin
    • Paclitaxel and Cisplatin
    • Jinan, Shandong, China
      Qilu Hospital of Shandong University
    Apr 19, 2022

    Esophagus Squamous Cell Carcinoma Trial in Huai'an (raltitrexed)

    Active, not recruiting
    • Esophagus Squamous Cell Carcinoma
    • Huai'an, Jiangsu, China
      Huai'an First Hospital
    Apr 5, 2021

    Histologically Confirmed Unresectable or Metastatic Squamous Cell Carcinoma of the Esophagus Who Failed on Standard Treatment

    Active, not recruiting
    • Histologically Confirmed Unresectable or Metastatic Squamous Cell Carcinoma of the Esophagus Who Failed on Standard Treatment
    • Seoul, Korea, Republic of
      Yonsei University Health System, Severance Hospital
    May 5, 2021

    Sequence and Time-of-day Infusion of immunoCHemotherapy Affect

    Completed
    • Esophagus Cancer
      • Guangzhou, Guangdong, China
        Guangdong Provincial People's Hospital
      Nov 24, 2022

      Esophagus Adenocarcinoma, Esophagus Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Dallas

      Recruiting
      • Esophagus Adenocarcinoma
      • +2 more
      • Dallas, Texas
        Dallas VA Medical Center
      Nov 2, 2021

      Squamous Cell Cancers Receiving Systemic Therapy

      Active, not recruiting
      • Cancer
      • +4 more
        • Toronto, Ontario, Canada
          Princess Margaret Cancer Centre
        Apr 11, 2021

        Squamous Cell Carcinoma of Esophagus Trial in Hong Kong (Andrographis Paniculata)

        Completed
        • Squamous Cell Carcinoma of Esophagus
        • Andrographis Paniculata
        • Hong Kong, Outside Of US & Canada, China
          Department of Surgery, Faculty of Medicine, The Chinese Universi
        Nov 5, 2021

        Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma Trial in Chengdu (Camrelizumab, Dalpiciclib 100mg,

        Recruiting
        • Esophageal Squamous Cell Carcinoma
        • Head and Neck Squamous Cell Carcinoma
        • Chengdu, Sichuan, China
          West China Hospital, Sichuan University
        Oct 25, 2023

        Esophageal Diseases, Esophagus SCC Trial in Moshi (Cytosponge™)

        Completed
        • Esophageal Diseases
        • Esophagus SCC
        • Cytosponge™
        • Moshi, Tanzania
          Majengo Unit, Kilimanjaro Clinical Research Institute
        Aug 24, 2021

        Minimal Residual Disease, Esophageal Squamous Cell Carcinoma Trial in Guangzhou

        Not yet recruiting
        • Minimal Residual Disease
        • Esophageal Squamous Cell Carcinoma
          • Guangzhou, Guangdong, China
            Guangdong Provincial People's Hospital
          Jun 10, 2023

          Tumor, Esophagus, Malignant Esophagus Tumor, Tumor, Esophageal Trial in Amsterdam (Bintrafusp alfa)

          Recruiting
          • Neoplasm, Esophagus
          • +2 more
          • Bintrafusp alfa
          • Amsterdam, Noord-Holland, Netherlands
            Amsterdam UMC
          Jan 15, 2021